⌘K
Loading ticker…
As of 2026-08-24, Celldex Therapeutics, Inc (CLDX) has a 3-month relative strength percentile of 89 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 67. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.2%, relative volume 0.43×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
CLDX is in a stage 2 uptrend, week 10. Currently in a 8-day base; basing ADR 4.1% (broad 4.2%). VCP detected: no. RS line below base-start high. Distance from 50d / 200d: 7.5% / 31.5%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
CLDX is held by 22 ETFs as of May 2026. Top owner: VTWO at 0.07% weight, $12M notional. Top 3 carry $30M.
Held by 56 ETFs · $271M across latest filings · largest weight 3.16% (SURI).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.07% | $12M | — |
| SCHASchwab U.S. Small-Cap ETF | 0.05% | $12M | — |
| VHTVanguard Health Care ETF | 0.03% | $6M | — |
| SBIO | 1.33% | $2M | +0.04 pp |
| VTWV | 0.15% | $2M | +0.01 pp |
| ESML | 0.06% | $2M | — |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $1M | — |
| ONEQ | 0.01% | $827K | — |
| GSSC | 0.02% | $206K | new |
| VTHRVanguard Russell 3000 ETF | 0.00% | $204K | — |
Showing 10 of 22 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CLDX Jan avg: -6.21% median: -6.26% win: 0% σ: 4.85% n: 4 2022-04-12 → 2026-07-31 | CLDX Feb avg: 9.97% median: 9.72% win: 50% σ: 23.76% n: 4 2022-04-12 → 2026-07-31 | CLDX Mar avg: -8.73% median: -12.22% win: 25% σ: 9.60% n: 4 2022-04-12 → 2026-07-31 | CLDX Apr avg: -3.13% median: -10.62% win: 40% σ: 11.96% n: 5 2022-04-12 → 2026-07-31 | CLDX May avg: -8.46% median: -5.04% win: 20% σ: 9.20% n: 5 2022-04-12 → 2026-07-31 | CLDX Jun avg: 10.75% median: 11.14% win: 100% σ: 6.16% n: 5 2022-04-12 → 2026-07-31 | CLDX Jul avg: 6.29% median: 4.21% win: 100% σ: 4.82% n: 5 2022-04-12 → 2026-07-31 | CLDX Aug avg: -3.31% median: -0.29% win: 50% σ: 12.57% n: 4 2022-04-12 → 2026-07-31 (current) | CLDX Sep avg: -2.37% median: -4.45% win: 25% σ: 14.68% n: 4 2022-04-12 → 2026-07-31 | CLDX Oct avg: -2.39% median: -5.61% win: 50% σ: 21.35% n: 4 2022-04-12 → 2026-07-31 | CLDX Nov avg: 10.10% median: 5.44% win: 100% σ: 12.40% n: 4 2022-04-12 → 2026-07-31 | CLDX Dec avg: 11.02% median: 10.34% win: 75% σ: 17.91% n: 4 2022-04-12 → 2026-07-31 |